Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.43 USD
Change Today +0.28 / 3.44%
Volume 145.1K
TNXP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Open
$8.16
Previous Close
$8.15
Day High
$8.56
Day Low
$8.01
52 Week High
08/26/14 - $15.21
52 Week Low
10/20/14 - $5.33
Market Cap
155.8M
Average Volume 10 Days
312.6K
EPS TTM
$-2.89
Shares Outstanding
18.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TONIX PHARMACEUTICALS HOLDIN (TNXP)

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system in the United States. The company develops TNX-102 SL, a sublingual tablet formulation, which is in Phase 3 clinical development stage for the treatment of fibromyalgia; and Phase 2 clinical development stage for the treatment of post-traumatic stress disorder. It is also involved in the development of TNX-201, an oral formulation of (R)-isometheptene mucate for the treatment of episodic tension-type headache, which is in Phase 2 clinical development stage. In addition, the company has a pipeline of various other product candidates, including TNX-301, a fixed dose combination drug product for the treatment of alcohol abuse and dependence. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.

16 Employees
Last Reported Date: 02/27/15
Founded in 2007

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $541.9K
Chief Financial Officer and Treasurer
Total Annual Compensation: $413.3K
Chief Scientific Officer, Controller and Secr...
Total Annual Compensation: $261.7K
Compensation as of Fiscal Year 2014.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Pharmaceuticals Appoints Mark T. Edgar as Senior Vice President of Product Development

Tonix Pharmaceuticals Holding Corp. has appointed Mark T. Edgar, PhD to the newly-created position of Senior Vice President of Product Development. Dr. Edgar brings to Tonix over 25 years of experience in pharmaceutical development and commercialization. He joins Tonix from M.T. Edgar Consulting, where he provided pharmaceutical development support for over 46 companies, including Tonix, across a wide variety of formulations and therapeutic indications since founding the firm in 2003.

Tonix Pharmaceuticals Holding Corp Mulls Acquisitions

Tonix Pharmaceuticals Holding Corp (NasdaqGM:TNXP) has filed a follow-on equity offering and intends to use the net proceeds for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

Tonix Pharmaceuticals Holding Corp. Presents Non-Clinical Data on TNX-201

Tonix Pharmaceuticals Holding Corp. announced that it presented non-clinical data from its TNX-201 (dexisometheptene mucate) program in two posters at the 57th Annual Scientific Meeting of the American Headache Society in Washington, DC. Tonix is currently evaluating TNX-201 in a Phase 2 proof-of-concept (POC) study in episodic tension-type headache. The active ingredient in TNX-201, dexisometheptene mucate, contains (R)-isometheptene, or (R)-IMH, a single optical isomer of isometheptene. Racemic IMH, a mixture of both the (R) and (S) isomers, had been widely used as a single-agent prescription medicine and as a component of combination drug products for many decades in the U.S. for various indications including tension-type headache. IMH was introduced as a pharmaceutical prior to 1962, and no products containing IMH are currently approved by the U.S. Food and Drug Administration (FDA) for any indication. TNX-201 is being developed as a new chemical entity for the treatment of episodic tension-type headache, based on current FDA drug registration requirements. Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache Key points: Data from receptor binding studies, taken together with the recent description of a decreased pain threshold in imidazoline-1 receptor (I1R) knock-out mice, suggest that I1R may be the primary site of action for racemic IMH's analgesic effects. Since (R)-IMH, the active ingredient in TNX-201, binds I1R with approximately 60-fold greater affinity than (S)-IMH, TNX-201 may be responsible for the therapeutic effect of racemic IMH.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $8.43 USD +0.28

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies
 

Industry Analysis

TNXP

Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONIX PHARMACEUTICALS HOLDIN, please visit www.tonixpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.